AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.5 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Crosstalk Between Parkinson's Disease and Colorectal Cancer: Genetic Mechanisms, Gut Microbiota, and Therapeutic Insights

Jiacheng Ying1, Zhengyuan Fang1, Cheng Zhang1, Xu Liu1, Jianzhi Cui1, Zezhi Li2 ( ), Jiayin Tang1 ( )
Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China

Jiacheng Ying and Zhengyuan Fang contributed equally to this work and share first authorship. Zezhi Li and Jiayin Tang are joint corresponding authors of this work.

Show Author Information

Abstract

This review summarizes the potential genes involved in both Parkinson's disease (PD) pathogenesis and colorectal cancer (CRC) carcinogenesis, focusing on the oncogenic mechanisms that may arise from PD gene dysfunctions. By investigating genes such as PRKN, PINK1, and DJ‐1, which influence pathways primarily related to oxidative stress, mitophagy, cell cycle regulation, and inflammation, this review provides insight into how PD genes may contribute to CRC tumorigenesis through interactions with gut microbes such as Bacillus subtilis and Clostridium butyricum. This review highlights a mechanistic bridge between neurodegeneration and cancer centered on mitochondrial dysfunction, mitophagy, and inflammation. The convergence of molecular mechanisms and gut microbiota in PD and CRC highlights promising avenues for microbiome‐targeted interventions alongside genetic and molecular approaches to advance novel diagnostic and therapeutic strategies for these two diseases. Importantly, therapeutic strategies should be considered in a holistic manner, as interventions for one disease may influence the course of another, and probiotics represent a unique modality with the potential to confer preventive and therapeutic benefits across both conditions.

Graphical Abstract

This review elucidates the crosstalk between Parkinson's disease and colorectal cancer, driven by shared genetics (PRKN, PINK1, DJ‐1) involving oxidative stress, cell cycle regulation, and inflammation. It identifies the gut microbiota—via functional amyloids and short‐chain fatty acids (SCFAs)—as a mechanistic bridge, offering insights for dual‐disease therapeutic strategies.

References

【1】
【1】
 
 
Health Care Science
Pages 495-513

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Ying J, Fang Z, Zhang C, et al. Crosstalk Between Parkinson's Disease and Colorectal Cancer: Genetic Mechanisms, Gut Microbiota, and Therapeutic Insights. Health Care Science, 2026, 5(5): 495-513. https://doi.org/10.1002/hcs2.70087

4

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus

Received: 18 December 2025
Revised: 29 April 2026
Accepted: 09 May 2026
Published: 18 July 2026
© 2026 The Author(s). Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.